Definium Therapeutics, Inc. Net Fee Amt
Definium Therapeutics, Inc. (DFTX) had Net Fee Amt of $111.17 thousand as of 2026-06-24, per its 424B5 filed 2026-06-24.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-06-24
- 2026-06-24: Net Fee Amt $111.17K.
| Period end | Net Fee Amt |
|---|---|
| 2026-06-24 | $111.17K 424B5 · filed 2026-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |